Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs

Keith T. Gagnon, David R Corey

Research output: Contribution to journalArticle

Abstract

After decades of research and development, synthetic nucleic acids are beginning to enjoy significant success in the clinic. Approved drugs have increased interest in the field, and many basic research studies have focused on synthetic nucleic acids to control the action of messenger RNA and noncoding RNAs. Unfortunately, experimental designs are often inadequate, resulting in misleading interpretation of data and unconvincing work that wastes resources and does little to advance the field. The goal of this commentary is to outline the problems facing many researchers, especially those new to the use of synthetic oligonucleotides. We describe the minimum control experiments necessary to build a strong case for real effects that are likely due to interactions at the intended molecular target. A common set of standards for preparing and judging experiments should facilitate better interpretation of data and publications that contribute positively to using synthetic nucleic acids as tools and drugs.

Original languageEnglish (US)
Pages (from-to)116-122
Number of pages7
JournalNucleic Acid Therapeutics
Volume29
Issue number3
DOIs
StatePublished - Jun 1 2019

Fingerprint

Double-Stranded RNA
Antisense Oligonucleotides
Nucleic Acids
Guidelines
Untranslated RNA
Experiments
Research
Oligonucleotides
Pharmaceutical Preparations
Design of experiments
Publications
Research Design
Research Personnel
Messenger RNA

Keywords

  • antisense oligonucleotide
  • controls
  • duplex RNA
  • guidelines

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Drug Discovery

Cite this

Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs. / Gagnon, Keith T.; Corey, David R.

In: Nucleic Acid Therapeutics, Vol. 29, No. 3, 01.06.2019, p. 116-122.

Research output: Contribution to journalArticle

@article{087ff3fd520e408d9a7724544c7ba62f,
title = "Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs",
abstract = "After decades of research and development, synthetic nucleic acids are beginning to enjoy significant success in the clinic. Approved drugs have increased interest in the field, and many basic research studies have focused on synthetic nucleic acids to control the action of messenger RNA and noncoding RNAs. Unfortunately, experimental designs are often inadequate, resulting in misleading interpretation of data and unconvincing work that wastes resources and does little to advance the field. The goal of this commentary is to outline the problems facing many researchers, especially those new to the use of synthetic oligonucleotides. We describe the minimum control experiments necessary to build a strong case for real effects that are likely due to interactions at the intended molecular target. A common set of standards for preparing and judging experiments should facilitate better interpretation of data and publications that contribute positively to using synthetic nucleic acids as tools and drugs.",
keywords = "antisense oligonucleotide, controls, duplex RNA, guidelines",
author = "Gagnon, {Keith T.} and Corey, {David R}",
year = "2019",
month = "6",
day = "1",
doi = "10.1089/nat.2018.0772",
language = "English (US)",
volume = "29",
pages = "116--122",
journal = "Nucleic Acid Therapeutics",
issn = "2159-3337",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs

AU - Gagnon, Keith T.

AU - Corey, David R

PY - 2019/6/1

Y1 - 2019/6/1

N2 - After decades of research and development, synthetic nucleic acids are beginning to enjoy significant success in the clinic. Approved drugs have increased interest in the field, and many basic research studies have focused on synthetic nucleic acids to control the action of messenger RNA and noncoding RNAs. Unfortunately, experimental designs are often inadequate, resulting in misleading interpretation of data and unconvincing work that wastes resources and does little to advance the field. The goal of this commentary is to outline the problems facing many researchers, especially those new to the use of synthetic oligonucleotides. We describe the minimum control experiments necessary to build a strong case for real effects that are likely due to interactions at the intended molecular target. A common set of standards for preparing and judging experiments should facilitate better interpretation of data and publications that contribute positively to using synthetic nucleic acids as tools and drugs.

AB - After decades of research and development, synthetic nucleic acids are beginning to enjoy significant success in the clinic. Approved drugs have increased interest in the field, and many basic research studies have focused on synthetic nucleic acids to control the action of messenger RNA and noncoding RNAs. Unfortunately, experimental designs are often inadequate, resulting in misleading interpretation of data and unconvincing work that wastes resources and does little to advance the field. The goal of this commentary is to outline the problems facing many researchers, especially those new to the use of synthetic oligonucleotides. We describe the minimum control experiments necessary to build a strong case for real effects that are likely due to interactions at the intended molecular target. A common set of standards for preparing and judging experiments should facilitate better interpretation of data and publications that contribute positively to using synthetic nucleic acids as tools and drugs.

KW - antisense oligonucleotide

KW - controls

KW - duplex RNA

KW - guidelines

UR - http://www.scopus.com/inward/record.url?scp=85066607066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066607066&partnerID=8YFLogxK

U2 - 10.1089/nat.2018.0772

DO - 10.1089/nat.2018.0772

M3 - Article

C2 - 30907681

AN - SCOPUS:85066607066

VL - 29

SP - 116

EP - 122

JO - Nucleic Acid Therapeutics

JF - Nucleic Acid Therapeutics

SN - 2159-3337

IS - 3

ER -